News & Updates

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

Treatment with statin results in a decrease in major vascular events following acute ischaemic stroke, even in patients with low or well-controlled low-density lipoprotein cholesterol (LDL-C), as shown in a study presented at ISC 2023.

In an international multi-database cohort study, direct oral anticoagulants (DOACs) demonstrated comparable efficacy and safety with vitamin K antagonists (VKAs) for octogenarians with venous thromboembolism (VTE).

Use of doxycycline as postexposure prophylaxis (PEP) results in a significant decrease in the incidence of Chlamydia trachomatis (CT) and syphilis and demonstrates a significant impact on the incidence of Neisseria gonorrhoeae (GC), reports a study presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI). Meningococcal B vaccine also helps lower the incidence of GC.

In the ARAMIS* trial, dual antiplatelet therapy (DAPT) using clopidogrel and aspirin was noninferior to intravenous thrombolysis (IVT) using alteplase in Chinese patients with minor nondisabling ischaemic stroke presenting within 4.5 hours of symptom onset.

The incidence of sexually transmitted infection (STI) over the first 4 years of pre-exposure prophylaxis (PrEP) use remains high and stable, but the incidence of chlamydia and gonorrhea has slightly decreased among daily PrEP users, as shown in a study presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI).